0000950170-23-058894.txt : 20231103
0000950170-23-058894.hdr.sgml : 20231103
20231103165005
ACCESSION NUMBER: 0000950170-23-058894
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231030
FILED AS OF DATE: 20231103
DATE AS OF CHANGE: 20231103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: King Michael
CENTRAL INDEX KEY: 0001998530
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39871
FILM NUMBER: 231377090
MAIL ADDRESS:
STREET 1: 2100 EAST 54TH STREET NORTH
CITY: SIOUX FALLS
STATE: SD
ZIP: 57104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SAB Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001833214
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 853899721
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 EAST 54TH STREET NORTH
CITY: SIOUX FALLS
STATE: SD
ZIP: 57104
BUSINESS PHONE: 605-679-6980
MAIL ADDRESS:
STREET 1: 2100 EAST 54TH STREET NORTH
CITY: SIOUX FALLS
STATE: SD
ZIP: 57104
FORMER COMPANY:
FORMER CONFORMED NAME: Big Cypress Acquisition Corp.
DATE OF NAME CHANGE: 20201120
4
1
ownership.xml
4
X0508
4
2023-10-30
0001833214
SAB Biotherapeutics, Inc.
SABS
0001998530
King Michael
2100 E 54TH STREET NORTH
SIOUX FALLS
SD
57104
false
true
false
false
CHIEF FINANCIAL OFFICER
false
Employee Stock Option (right to buy)
0.798
2023-10-30
4
A
false
850000
0
A
2033-10-30
Common Stock
850000
850000
D
Represents options to purchase shares of common stock of the Registrant pursuant to the Registrant's 2021 Omnibus Equity Incentive Plan. The exercise price of the options was determined as of the date that the compensation committee of the board of directors of the Registrant approved the award, October 19, 2023. The award was contingent upon the Reporting Person's commencement of service as Chief Financial Officer of the Registrant, which occurred on October 30, 2023.
The shares underlying the option vest over a four-year period, with 1/4 vesting on the one-year anniversary date from the Reporting Person's commencement of service as Chief Financial Officer (October 30, 2024), and the remainder vesting thereafter in equal monthly installments over a three year period.
/s/ Michael G. King, Jr.
2023-11-03